Pivotal data from larger Novavax trial due early 2021

28 October 2020

COVID-19 vaccine developer Novavax (Nasdaq: NVAX) has provided an update on the Phase III program for NVX-CoV2373, a stable, prefusion protein made using the firm’s nanoparticle technology.

In the UK, the firm has now enrolled 5,500 volunteers and has expanded the study to include 15,000 participants, with full enrollment expected by the end of November.

Event-driven interim data is expected by early in the first quarter 2021, and these results are expected to serve as the basis for global licensure.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK